Online inquiry

IVTScrip™ mRNA-Anti-GP, c4G7-N(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ5016MR)

This product GTTS-WQ5016MR is a type of mRNA modified with N1-Methylpseudo-UTP, which ecodes the monoclonal antibody that targets GP gene. The antibody can be applied in Ebola virus infection research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 1
Species Chimeric
RefSeq NP_066246.1
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 911829
UniProt ID Q05320
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-GP, c4G7-N(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) (GTTS-WQ5016MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ7491MR IVTScrip™ mRNA-Anti-TGFB, GC-1008(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA GC-1008
GTTS-WQ9067MR IVTScrip™ mRNA-Anti-IGF1R, IMC-A12(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA IMC-A12
GTTS-WQ13756MR IVTScrip™ mRNA-Anti-ANGPTL3, REGN 1500(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA REGN 1500
GTTS-WQ6021MR IVTScrip™ mRNA-Anti-IL12B, CNTO 1275(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA CNTO 1275
GTTS-WQ4927MR IVTScrip™ mRNA-Anti-TNFRSF17, C11D5.3 scFv-8A-F9Z CAR(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA C11D5.3 scFv-8A-F9Z CAR
GTTS-WQ9856MR IVTScrip™ mRNA-Anti-CD37, K7153A(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA K7153A
GTTS-WQ2905MR IVTScrip™ mRNA-Anti-IL17RA, AMG827(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA AMG827
GTTS-WQ6620MR IVTScrip™ mRNA-Anti-CD79B, DCDS0780A(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA DCDS0780A
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW